BPC-157 Reconstitution Calculator

BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV, MW 1419) derived from gastric juice with cytoprotective, pro-angiogenic, and NO-modulating activity in preclinical models. It is not FDA-approved, has no validated dosing regimen, and no completed Phase II trial; published human data derive from fewer than 30 subjects across three uncontrolled pilot studies. It is sold through unregulated channels and marketed for soft-tissue healing, recovery, and GI repair, mostly extrapolated from animal data.

No validated human dose exists. Preclinical rat studies use 10 µg/kg or 10 ng/kg daily via intraperitoneal, oral (drinking water), or topical routes, spanning a 1,000-fold range with reported efficacy (animal). Human pilots used an IV infusion of 10 mg on day 1 and 20 mg on day 2, and a single 10 mg intravesical injection (human pilot). (community protocol): 250–500 mcg/day subcutaneous or oral, single or split dose; 250–500 mcg injected locally near the injury site. No body-weight-adjusted human regimen is established.

Both routes are active in animals; BPC-157 is unusually stable in gastric juice, supporting oral administration. Formal pharmacokinetics: plasma half-life under 30 min, linear kinetics, and intramuscular bioavailability of 14–19% (rat) and 45–51% (dog). (community protocol): oral at 500 mcg daily for gut/systemic indications; subcutaneous 250–500 mcg 1–2×/day for musculoskeletal work, often paired with a local injection at the injury. No human route-comparison data exist.

Preclinical toxicology reported no adverse effects across organ systems, and the two published human pilots (IV up to 20 mg; 10 mg bladder injection) reported none. However, controlled human safety data are absent, and grey-market sourcing carries real risks: contamination, impurities, inaccurate dosing, and theoretical concerns including pathological angiogenesis and carcinogenesis. Long-term human safety is unknown.

Human data do not define a treatment duration. Rat tendon studies used 4-week courses daily. (community protocol): 4–8 week cycles followed by 2–4 weeks off, repeated as needed; indefinite continuous use has no evidentiary basis. Unregulated product quality is the main practical constraint.

The evidence gap is large. 67% of the identified literature is preclinical animal models. Small human reports: 7 of 12 patients had >6 months of pain relief after intra-articular knee injection (retrospective, uncontrolled); 12 of 12 interstitial cystitis patients reported symptom resolution after one 10 mg bladder injection. Reviews conclude musculoskeletal benefits remain unsubstantiated by controlled trials.

In the only head-to-head preclinical study (rat Achilles transection, 4 weeks), TB-500 (60 µg/kg/day IP) produced significant biomechanical improvement and lower histopathology scores; BPC-157 (10 µg/kg/day IP) improved numerically but not significantly; the combination added no benefit over either alone (animal). Both share angiogenic and cell-migration mechanisms. No human comparative data exist.

Yes, WADA prohibits BPC-157 under Class S0 (unapproved substances). Doping-control laboratories have validated methods for it in urine, with a detection limit of 0.1 ng/mL and stability in urine of at least 4 days. If you are subject to testing, assume a positive result is possible for several days after the last dose; there is no established clearance window from official bodies (community protocol).